<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30810673</article-id><article-id pub-id-type="pmc">6385825</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0230</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Relation Between Echocardiographic Epicardial Fat Thickness and
CHA<sub>2</sub>DS<sub>2</sub>-VASc Score in Patients with Sinus
Rhythm</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6480-4935</contrib-id><name><surname>Aksoy</surname><given-names>Fatih</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Guler</surname><given-names>Serdar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kahraman</surname><given-names>Fatih</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Oskay</surname><given-names>T&#x000fc;lay</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Varol</surname><given-names>Ercan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><aff id="aff1">
<label>1</label> Department of Cardiology, Suleyman Demirel University, Medical
School, Isparta, Turkey. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: <bold>Fatih Aksoy</bold>,
http://orcid.org/0000-0002-6480-4935, Suleyman Demirel Universitesi, Tip
Fakultesi, &#x000c7;&#x000fc;n&#x000fc;r, Do&#x0011f;u Yerle&#x0015f;kesi, Isparta,
Turkey - Zip Code: 32200. E-mail: <email>dr.aksoy@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><history><date date-type="received"><day>07</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>24</day><month>9</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To evaluate the predictive value of epicardial fat thickness (EFT) in
CHA<sub>2</sub>DS<sub>2</sub>-VASc (congestive heart failure,
hypertension, age &#x02265;75 years, diabetes mellitus, previous stroke or
transient ischemic attack, vascular disease, age 65-74 years, sex category)
score risk groups.</p></sec><sec><title>Methods</title><p>A total of 158 consecutive patients (75 females, 83 males, mean age
70.8&#x000b1;6.3 years) admitted routinely for cardiologic control were
divided into two groups according to their
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores (scores 0 and 1 were regarded as
low risk, and score &#x02265;2 as high risk). One hundred twenty-five of 158
patients had a high-risk score.</p></sec><sec><title>Results</title><p>Mean EFT was significantly higher in the high-risk group than in the low-risk
group (4.34&#x000b1;0.62 <italic>vs</italic>. 5.37&#x000b1;1.0;
<italic>P</italic>&#x0003c;0.001). EFT was positively correlated with
CHA<sub>2</sub>DS<sub>2</sub>-VASc score (r=0.577,
<italic>P</italic>&#x0003c;0.001). According to receiver operating
characteristics (ROC) analysis, EFT value of 4.4 mm was found to be
predictive of high risk in CHA<sub>2</sub>DS<sub>2</sub>-VASc score with 80%
of sensitivity and 79% of specificity (C-statistic = 0.875,
<italic>P</italic>&#x0003c;0.001, 95% confidence interval [CI] = 0.76-0.90).
And according to multivariate logistic regression analysis, EFT was an
independent predictor of high thromboembolic risk in terms of
CHA<sub>2</sub>DS<sub>2</sub>-VASc score.</p></sec><sec><title>Conclusion</title><p>Our findings suggest that echocardiographic EFT measurement could provide
additional information on assessing cardiovascular risks, such as
thromboembolic events, and individuals with increased EFT should receive
more attention to reduce unfavorable cardiovascular risk factors and the
development of future cardiovascular events.</p></sec></abstract><kwd-group><kwd>Thromboembolism/Prevention &#x00026; Control</kwd><kwd>Pericardium</kwd><kwd>Adipose Tissue</kwd><kwd>Risk Assessment</kwd></kwd-group></article-meta></front><body><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACEi</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Angiotensin-converting
enzyme inhibitors</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EFT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Epicardial fat
thickness</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HDL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= High-density
lipoprotein</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ARB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Angiotensin II receptor
blockers</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IQR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Inter-quartile
range</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ASA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acetylsalicylic
acid</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IVS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interventricular
septum</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AUC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Area under the
curve</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left atrial/atrium</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body mass index</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LDL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Low-density
lipoprotein</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery
disease</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEDD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular end
diastolic diameter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Congestive heart
failure, hypertension, age &#x02265;75years, diabetes mellitus, previous
stroke or transient ischemic attack, vascular disease, age 65-74 years,
sex category</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVESD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular end
systolic diameter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVPW</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
posterior wall</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Computed tomography</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NT-proBNP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= N-terminal pro b-type
natriuretic peptide</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DBP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Diastolic blood
pressure</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NVAF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Non-valvular atrial
fibrillation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EAT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Epicardial adipose
tissue</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OA/NOA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Oral anticoagulant/New
oral anticoagulant</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EDTA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Ethylenediaminetetraacetic acid</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Odds ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ejection fraction</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ROC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Receiver operating
characteristics</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SBP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Systolic blood
pressure</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TIA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transient ischemic
attack</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Ischemic stroke is a leading cause of death and long-term disability
worldwide<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Control of risk factors is of particular importance
for the prevention of cerebrovascular diseases. It is possible to stop progression
or prevent these diseases by elimination or modification of modifiable risk factors
in the light of treatment goals.</p><p>Epicardial adipose tissue (EAT), located between the myocardium and visceral
pericardium, has emerged as an important cardiovascular risk predictor, in view of
producing and releasing several adipocytokines<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. The importance of epicardial fat thickness
(EFT) has been shown in recent years. Increased EFT is associated with hypertension,
insulin resistance, and thromboembolic processes such as stroke and acute coronary
syndrome<sup>[<xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>The CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score is a cheap and easy scoring system
which is calculated by assigning 1 point for each: congestive heart failure
(ejection fraction [EF] &#x0003c; 40%), hypertension, age between 65 and 74 years,
diabetes mellitus, vascular disease (myocardial infarction or peripheral arterial
disease), and female sex; and 2 points for: a history of stroke or transient
ischemic attack (TIA) and age &#x0003e; 75 years. The CHA<sub>2</sub>DS<sub>2</sub>-VASc
risk score is used to predict the thromboembolism risk in non-valvular atrial
fibrillation (NVAF) patients<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>The present study aimed to determine whether EFT is more closely associated with
high-risk patients according to the CHA<sub>2</sub>DS<sub>2</sub>-VASc risk
score.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The 158 consecutive patients (75 females, 83 males, mean age 70.8&#x000b1;6.3 years)
admitted to the outpatient clinic of the Suleyman Demirel University Hospital,
Department of Cardiology, and referred to our echocardiography laboratory due to
suspicion of heart disease between June 2014 and May 2015 were enrolled in this
prospective study. All patients underwent medical history assessment, physical
examination, anthropometric measurements, electrocardiogram, and echocardiographic
evaluation. The study was approved by the institutional ethics committee and all
patients gave their informed consent. Exclusion criteria were pericardial effusion,
poor echocardiographic window, history of chronic renal and liver disease, moderate
to severe mitral and aortic regurgitation, moderate to severe mitral and aortic
stenosis, malignancy, systemic or pulmonary embolism, chronic hematological
diseases, acute or chronic inflammatory disease, autoimmune disease,
hyperparathyroidism, hypercalcemia, hyperphosphatemia, and a prosthetic valve.
According to CHA<sub>2</sub>DS<sub>2</sub>-VASc score, patients were divided into
two groups: scores 0 and 1 were regarded as low risk, and score &#x02265;2 as high
risk.</p><sec><title>Echocardiography</title><p>The M-mode, two-dimensional, and Doppler echocardiographic examinations were
obtained by an ultrasound machine (Philips iE 33 xMatrix) to assess left atrial
(LA) diameter, interventricular septum (IVS) thickness, left ventricular
posterior wall (LVPW) thickness, left ventricular end diastolic diameter
(LVEDD), left ventricular end systolic diameter (LVESD), and left ventricular
EF. LA and left ventricular dimensions and left ventricular EF were measured by
M-mode echocardiography in the parasternal long axis view by using the American
Echocardiography Society M-mode technique<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. The presence of mitral and aortic
insufficiency was evaluated by Doppler color flow mapping. EFT was identi&#x0fb01;ed
echocardiographically as the echo-free space between the outer wall of the
myocardium and the visceral layer of pericardium. EFT was measured at the point
on the free wall of the right ventricle along the midline of the ultrasound
beam, perpendicular to the aortic annulus at the end of
systole<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> (<xref ref-type="fig" rid="f1">Figure 1</xref>).
As Iacobellis et al.<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> suggested, epicardial fat is best measured at
end-systole, because it is compressed during diastole. The average value of
three cardiac cycles was determined as EFT.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Measurement of epicardial fat thickness by echocardiography.</p></caption><graphic xlink:href="rbccv-34-01-0041-g01"/></fig>
</p></sec><sec><title>Blood Sampling</title><p>Blood samples were drawn from the antecubital vein by careful venipuncture in a
21 G sterile syringe without stasis at 08.00-10.00 AM after a fasting period of
12 h. Glucose, creatinine, and lipid profiles were determined by standard
methods. Hemogram parameters were measured in a blood sample collected in
dipotassium ethylenediaminetetraacetic acid (EDTA) tubes (Vacuette). An
automatic blood counter (Beckman-Coulter Co, Miami, FL, USA) was used for whole
blood counts.</p></sec><sec><title>Statistical Analysis</title><p>SPSS software package program, version 16.0, was used in this study's statistical
analyses. Categorical variables were expressed as frequency (%) and compared
using the &#x003c7;<sup>2</sup> test. A Kolmogorov-Smirnov test was used to test
the distribution of numeric variables, and those with normal distribution were
expressed as mean &#x000b1; standard deviation and were compared using the
Student's <italic>t</italic>-test. Data without normal distribution were
expressed as median (inter-quartile range [IQR] of 25%-75% percentiles) and were
compared using the Mann-Whitney U test. In all statistical analyses,
<italic>P</italic> values &#x0003c;0.05 were considered as statistically
significant. Univariate analysis of binary logistic regression was carried out
to identify which factors were associated with high risk according to
CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score. After including each of these
potential confounding factors, backward conditional binary logistic regression
analysis was performed to estimate the odds ratio (OR) and 95% confidence
interval (CI) for high risk according to CHA<sub>2</sub>DS<sub>2</sub>-VASc risk
score. Receiver operating characteristics (ROC) curve analysis was used to
analyze the prognostic value of EFT for high risk according to
CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score. C-Statistic (area under the
curve [AUC]) was presented as a unified estimate of sensitivity and specificity.
According to the cut-off value that was obtained by a ROC curve analysis, the
study population could be segregated into two groups, as low risk and high risk.
The correlations between CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score, EFT, and
other clinical, laboratory, and echocardiographic parameters were performed with
Pearson and Spearman correlation analysis when appropriate.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Baseline clinical features of the study population were summarized in <xref rid="t1" ref-type="table">Table 1</xref>. Age, female gender, hypertension, and
diabetes mellitus were seen more often in high CHA<sub>2</sub>DS<sub>2</sub>-VASc
score group than in low CHA<sub>2</sub>DS<sub>2</sub>-VASc score group. Only
&#x003b2;-blocker and clopidogrel usages were significantly higher in the high
CHA<sub>2</sub>DS<sub>2</sub>-VASc score group. Laboratory findings of the study
population were summarized in <xref rid="t2" ref-type="table">Table 2</xref>. There
was no statistically significant difference between the two groups except for
fasting glucose (<italic>P</italic>=0.04). Cholesterol levels were similar between
high- and low-risk groups according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score.
Echocardiographic findings of the study population were summarized in <xref rid="t3" ref-type="table">Table 3</xref>. LA diameter was significantly higher
in patients with high-risk score than in low-risk score subjects in terms of
CHA<sub>2</sub>DS<sub>2</sub>-VASc score (33&#x000b1;5.6 <italic>vs</italic>.
36&#x000b1;4.3 mm, respectively; <italic>P</italic>&#x0003c;0.001). IVS thickness was
significantly higher in patients with high risk than in low-risk subjects
(10&#x000b1;1.0 <italic>vs</italic>. 11&#x000b1;1.4 mm, respectively;
<italic>P</italic>&#x0003c;0.001). LVEDD was significantly higher in patients with
high risk than in low-risk subjects (44&#x000b1;1.7 <italic>vs</italic>.
45&#x000b1;3.7 mm, respectively; <italic>P</italic>&#x0003c;0.001). LVESD was
significantly higher in patients with high risk than in low-risk subjects
(27&#x000b1;1.7 <italic>vs</italic>. 28&#x000b1;3.3 mm, respectively; P&#x0003c;0.001). EFT
was significantly higher in patients with high risk than in low-risk subjects
(4.34&#x000b1;0.62 <italic>vs</italic>. 5.37&#x000b1;1.0 mm, respectively;
<italic>P</italic>&#x0003c;0.001). Correlation analysis between EFT and
CHA<sub>2</sub>DS<sub>2</sub>-VASc score with other clinical and
echocardiographic parameters was shown in <xref rid="t4" ref-type="table">Table
4</xref>. EFT was positively correlated with CHA<sub>2</sub>DS<sub>2</sub>-VASc
score (r=0.577, <italic>P</italic>&#x0003c;0.001). Also, EFT was positively correlated
with age (r=0.520, <italic>P</italic>&#x0003c;0,001), LA (r=0.264,
<italic>P</italic>&#x0003c;0.001), IVS (r=356, <italic>P</italic>&#x0003c;0.001), LVESD
(r=0.262, <italic>P</italic>=0.011), and aorta diameter (r=0.22,
<italic>P</italic>&#x0003c;0.001). Negative correlation was found between EFT and left
ventricular EF (r=-0.199, <italic>P</italic>=0.012).
CHA<sub>2</sub>DS<sub>2</sub>-VASc score was positively correlated with age
(r=0.578, <italic>P</italic>&#x0003c;0,001), LA (r=0.235, <italic>P</italic>=0.003), IVS
(r=386, <italic>P</italic>&#x0003c;0.001), LVESD (r=0.337, <italic>P</italic>&#x0003c;0.001),
and aorta diameter (r=0.229, <italic>P</italic>=0.004). Negative correlation was
found between CHA<sub>2</sub>DS<sub>2</sub>-VASc score and left ventricular EF
(r=-0.154, <italic>P</italic>=0.05). Univariate and multivariate regression analyses
results were shown in <xref rid="t5" ref-type="table">Table 5</xref>. Older age, LA
diameter, aorta diameter, left ventricular EF, IVS diameter, and EFT achieved
statistical significance in the univariate logistic analysis. Then, multivariate
analysis was carried out with these variables; age and EFT were found to be
independent predictors of high risk for CHA<sub>2</sub>DS<sub>2</sub>-VASc
classification. According to ROC analysis, EFT value of 4.4 mm was predictive of
high risk of CHA<sub>2</sub>DS<sub>2</sub>-VASc score with 80% of sensitivity and
79% of specificity (C-statistic = 0.875, <italic>P</italic>&#x0003c;0.001, 95 % CI=
0.76-0.90; <xref ref-type="fig" rid="f2">Figure 2</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline clinical features of the study population.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Low CHA<sub>2</sub>DS<sub>2</sub>-VASc score
(n=33)</th><th align="center" rowspan="1" colspan="1">High CHA<sub>2</sub>DS<sub>2</sub>-VASc score
(n=125)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="center" rowspan="1" colspan="1">64&#x000b1;4.1</td><td align="center" rowspan="1" colspan="1">72&#x000b1;5.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Female gender, n (%)</td><td align="center" rowspan="1" colspan="1">9 (26)</td><td align="center" rowspan="1" colspan="1">66 (53)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="center" rowspan="1" colspan="1">5 (14)</td><td align="center" rowspan="1" colspan="1">85 (70)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">4 (11)</td><td align="center" rowspan="1" colspan="1">58 (46)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia, n (%)</td><td align="center" rowspan="1" colspan="1">18 (52)</td><td align="center" rowspan="1" colspan="1">56 (47)</td><td align="center" rowspan="1" colspan="1">0.359</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, n (%)</td><td align="center" rowspan="1" colspan="1">7 (20)</td><td align="center" rowspan="1" colspan="1">53 (42)</td><td align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">CAD, n (%)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">31 (24)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke/TIA, n (%)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">11 (8)</td><td align="center" rowspan="1" colspan="1">0.069</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">29&#x000b1;3.5</td><td align="center" rowspan="1" colspan="1">30&#x000b1;7.0</td><td align="center" rowspan="1" colspan="1">0.209</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">109&#x000b1;9</td><td align="center" rowspan="1" colspan="1">122&#x000b1;17</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">73&#x000b1;6</td><td align="center" rowspan="1" colspan="1">76&#x000b1;10</td><td align="center" rowspan="1" colspan="1">0.109</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beat/min)</td><td align="center" rowspan="1" colspan="1">70&#x000b1;12</td><td align="center" rowspan="1" colspan="1">71&#x000b1;13</td><td align="center" rowspan="1" colspan="1">0.623</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>ASA</italic>, n (%)</td><td align="center" rowspan="1" colspan="1">17 (51)</td><td align="center" rowspan="1" colspan="1">49 (39)</td><td align="center" rowspan="1" colspan="1">0.183</td></tr><tr><td align="left" rowspan="1" colspan="1">Clopidogrel, n (%)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">20 (16)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>OA/NOA</italic>, n (%)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">8 (6)</td><td align="center" rowspan="1" colspan="1">0.146</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin, n (%)</td><td align="center" rowspan="1" colspan="1">8 (24)</td><td align="center" rowspan="1" colspan="1">32 (25)</td><td align="center" rowspan="1" colspan="1">0.535</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEi, n (%)</td><td align="center" rowspan="1" colspan="1">4 (12)</td><td align="center" rowspan="1" colspan="1">34 (27)</td><td align="center" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" rowspan="1" colspan="1">ARB, n (%)</td><td align="center" rowspan="1" colspan="1">5 (15)</td><td align="center" rowspan="1" colspan="1">32 (25)</td><td align="center" rowspan="1" colspan="1">0.159</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b2;-blocker, n (%)</td><td align="center" rowspan="1" colspan="1">6 (17)</td><td align="center" rowspan="1" colspan="1">55 (44)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>ACEi=angiotensin-converting enzyme inhibitors; ARB=angiotensin II
receptor blockers; ASA=Acetylsalicylic acid; BMI=body mass index;
CAD=coronary artery disease;
CHA<sub>2</sub>DS<sub>2</sub>-VASc=congestive heart failure,
hypertension, age &#x02265;75 years, diabetes mellitus, previous stroke
or transient ischemic attack, vascular disease, age 65-74 years, sex
category; DBP=diastolic blood pressure; OA/NOA=Oral anticoagulant/New
oral anticoagulant; SBP=systolic blood pressure; TIA=transient ischemic
attack</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Laboratory findings of the study population.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Low CHA<sub>2</sub>DS<sub>2</sub>-VASc score
(n=33)</th><th align="center" rowspan="1" colspan="1">High CHA<sub>2</sub>DS<sub>2</sub>-VASc score
(n=125)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hemoglobin, g/L</td><td align="center" rowspan="1" colspan="1">12.1&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">11.9&#x000b1;1.0</td><td align="center" rowspan="1" colspan="1">0.201</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count (x 10<sup>3</sup>/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">238&#x000b1;58</td><td align="center" rowspan="1" colspan="1">245&#x000b1;71</td><td align="center" rowspan="1" colspan="1">0.603</td></tr><tr><td align="left" rowspan="1" colspan="1">White blood cell count (x
10<sup>3</sup>/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">8251&#x000b1;2344</td><td align="center" rowspan="1" colspan="1">7730&#x000b1;2400</td><td align="center" rowspan="1" colspan="1">0.264</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose, mg/dL</td><td align="center" rowspan="1" colspan="1">111&#x000b1;34</td><td align="center" rowspan="1" colspan="1">128&#x000b1;62</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol, mg/dL</td><td align="center" rowspan="1" colspan="1">45&#x000b1;15</td><td align="center" rowspan="1" colspan="1">47&#x000b1;12</td><td align="center" rowspan="1" colspan="1">0.444</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol, mg/dL</td><td align="center" rowspan="1" colspan="1">114&#x000b1;43</td><td align="center" rowspan="1" colspan="1">111&#x000b1;36</td><td align="center" rowspan="1" colspan="1">0.763</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides, mg/dL</td><td align="center" rowspan="1" colspan="1">178&#x000b1;131</td><td align="center" rowspan="1" colspan="1">148&#x000b1;83</td><td align="center" rowspan="1" colspan="1">0.109</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>CHA<sub>2</sub>DS<sub>2</sub>-VASc=congestive heart failure,
hypertension, age &#x02265;75 years, diabetes mellitus, previous stroke
or transient ischemic attack, vascular disease, age 65-74 years, sex
category; HDL=high-density lipoprotein; LDL=low-density lipoprotein</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Echocardiographic findings of the study population.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Low CHA<sub>2</sub>DS<sub>2</sub>-VASc score
(n=33)</th><th align="center" rowspan="1" colspan="1">High CHA<sub>2</sub>DS<sub>2</sub>-VASc score
(n=125)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Left ventricular EF, %</td><td align="center" rowspan="1" colspan="1">60&#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">59&#x000b1; 3.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Aorta (mm)</td><td align="center" rowspan="1" colspan="1">24&#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">25&#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LA (mm)</td><td align="center" rowspan="1" colspan="1">33&#x000b1; 5.6</td><td align="center" rowspan="1" colspan="1">36&#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">IVS (mm)</td><td align="center" rowspan="1" colspan="1">10&#x000b1; 1.0</td><td align="center" rowspan="1" colspan="1">11&#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LVPW (mm)</td><td align="center" rowspan="1" colspan="1">9.3&#x000b1; .05</td><td align="center" rowspan="1" colspan="1">10&#x000b1; 0.8</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LVESD (mm)</td><td align="center" rowspan="1" colspan="1">27&#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">28&#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEDD (mm)</td><td align="center" rowspan="1" colspan="1">44&#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">45&#x000b1; 3.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">EFT (mm)</td><td align="center" rowspan="1" colspan="1">4.34&#x000b1; 0.62</td><td align="center" rowspan="1" colspan="1">5.37&#x000b1; 1.0</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CHA<sub>2</sub>DS<sub>2</sub>-VASc=congestive heart failure,
hypertension, age &#x02265;75 years, diabetes mellitus, previous stroke
or transient ischemic attack, vascular disease, age 65-74 years, sex
category; EF=ejection fraction; EFT=epicardial fat thickness;
IVS=interventricular septum; LA=left atrium; LVEDD=left ventricular end
diastolic diameter; LVESD=left ventricular end systolic diameter;
LVPW=left ventricular posterior wall</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Clinical and echocardiographic parameters showing the significant correlation
with EFT and CHA<sub>2</sub>DS<sub>2</sub>-VASc score.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">With EFT</th><th align="center" colspan="2" rowspan="1">With CHA<sub>2</sub>DS<sub>2</sub>-VASc
score</th></tr><tr><th align="center" rowspan="1" colspan="1">r</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">r</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">0.520</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.578</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LA</td><td align="center" rowspan="1" colspan="1">0.264</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.235</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">IVS</td><td align="center" rowspan="1" colspan="1">0.356</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.386</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LVESD</td><td align="center" rowspan="1" colspan="1">0.262</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">0.337</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEDD</td><td align="center" rowspan="1" colspan="1">0.188</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">0.202</td><td align="center" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF</td><td align="center" rowspan="1" colspan="1">-0.199</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">-0.154</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Aorta</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">0.229</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference</td><td align="center" rowspan="1" colspan="1">0.184</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.151</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="center" rowspan="1" colspan="1">0.156</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.172</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td><td align="center" rowspan="1" colspan="1">0.577</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.577</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>BMI=body mass index; CHA<sub>2</sub>DS<sub>2</sub>-VASc=congestive heart
failure, hypertension, age &#x02265;75 years, diabetes mellitus, previous
stroke or transient ischemic attack, vascular disease, age 65-74 years,
sex category; LVEF=left ventricular ejection fraction; EFT=epicardial
fat thickness; IVS=interventricular septum; LA=left atrium; LVEDD=left
ventricular end diastolic diameter; LVESD=left ventricular end systolic
diameter</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Predictors of CHA<sub>2</sub>DS<sub>2</sub>-VASc risk classification in
univariate and multivariate analyses.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">(95 % CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">(95 % CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">1.318</td><td align="center" rowspan="1" colspan="1">1.17-1.47</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.270</td><td align="center" rowspan="1" colspan="1">1.11-1.44</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Epicardial tissue thickness</td><td align="center" rowspan="1" colspan="1">7.01</td><td align="center" rowspan="1" colspan="1">2.89-16.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">1.61-10.28</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricular ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">0.876</td><td align="center" rowspan="1" colspan="1">0.76-0.997</td><td align="center" rowspan="1" colspan="1">0.045</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Left atrial length (mm)</td><td align="center" rowspan="1" colspan="1">1.161</td><td align="center" rowspan="1" colspan="1">1.05-1.27</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Aorta diameter</td><td align="center" rowspan="1" colspan="1">1.341</td><td align="center" rowspan="1" colspan="1">1.10-1.62</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">IVS</td><td align="center" rowspan="1" colspan="1">1.770</td><td align="center" rowspan="1" colspan="1">1.27-2.45</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>CI=confidence interval; IVS=interventricular septum; OR=odds ratio</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Receiver operating characteristics (ROC) curve with calculated area under
the curve (AUC) and optimal cut-off point for epicardial fat thickness
to identify the presence of high risk of CHA2DS2-VASc (congestive heart
failure, hypertension, age &#x02265;75 years, diabetes mellitus, previous
stroke or transient ischemic attack, vascular disease, age 65-74 years,
sex category) score. CI=confidence interval</p></caption><graphic xlink:href="rbccv-34-01-0041-g02"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In the present study, we examined EFT in patients with high- and low-risk
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores. We found out that EFT was
significantly higher in patients with high CHA<sub>2</sub>DS<sub>2</sub>-VASc score
than in those with low CHA<sub>2</sub>DS<sub>2</sub>-VASc score and that EFT was
positively correlated with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores.</p><p>EAT is a true visceral fat tissue, deposited around the heart and particularly around
the subepicardial coronary vessels. EAT is a complex organ, mainly composed of
adipocytes, but it also includes a neuronal network, stromavascular, immune and
inflammatory cells, all nourished by a rich microcirculation<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>EFT is associated with thromboembolic diseases, including cardiovascular and
neurovascular diseases<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Akil et al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> showed that EFT was significantly higher
in patients with ischemic stroke than in healthy controls. Akdag et
al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> investigated the association of EFT, inflammatory,
and thrombosis parameters with CHA<sub>2</sub>DS<sub>2</sub>-VASc score in NVAF
patients. They determined that EFT, inflammatory, and thrombosis parameters were
associated with the thromboembolic risk exhibited by
CHA<sub>2</sub>DS<sub>2</sub>-VASc score in NVAF patients. In our study, we
investigated the association of EFT with CHA<sub>2</sub>DS<sub>2</sub>-VASc score in
patients with sinus rhythm. Our results were similar with those from that study. EFT
was significantly higher in high CHA<sub>2</sub>DS<sub>2</sub>-VASc score than in
low CHA<sub>2</sub>DS<sub>2</sub>-VASc score among patients with sinus rhythm. EAT
is considered an endocrine and metabolically active organ. It is a source of several
bioactive molecules that can influence the myocardium and coronary
arteries<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Epicardial fat expresses and secretes a number of
cytokines, pro- and anti-inflammatory adipokines, vasoactive factors, and growth
factors<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Accordingly, inflammation appears to play an
important role in thromboembolic events, such as acute coronary syndrome and
stroke<sup>[<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>. As a result, increased inflammatory mediators from
EAT may have an important role in the pathogenesis of stroke and atherosclerosis. As
also mentioned before, EAT is strongly associated with the pathogenesis of
atherosclerosis due to sharing the same risk factors. In the present study, we have
shown that high thromboembolic risk according to CHA<sub>2</sub>DS<sub>2</sub>-VASc
score was positively correlated with EFT.</p><p>It has been shown that EAT is related to cardiovascular risk
factors<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. The studies using echocardiography to measure EFT
on the right ventricle showed relations with waist circumference and left
ventricular measurements<sup>[<xref rid="r15" ref-type="bibr">15</xref>-<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Our findings were similar to these studies. We
reported a strong relationship between EAT and age, diabetes mellitus, and
hypertension. CHA<sub>2</sub>DS<sub>2</sub>-VASc score includes these risk factors.
Similarly, Cetin et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> reported a significant association between EFT and
type 2 diabetic subjects with subclinical atherosclerosis. Dogan et
al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> showed that in patients with newly diagnosed
hypertension, increased EFT was significantly linked to impaired aortic elastic
properties. Iacobellis et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> showed a correlation between cholesterol levels
and EFT. However, the relationship between EFT and
CHA<sub>2</sub>DS<sub>2</sub>-VASc score was independent of cholesterol levels in
our study.</p><p>In the echocardiographic evaluation, EFT, LA length, aorta diameter, and IVS length
were correlated with CHA<sub>2</sub>DS<sub>2</sub>-VASc score and they are
independent risk factors for high thromboembolic risk in
CHA<sub>2</sub>DS<sub>2</sub>-VASc score, based on a multivariate analysis.
Accordingly, Altun et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> have shown a significant association between EFT,
N-terminal pro b-type natriuretic peptide (NT-proBNP) levels, and arterial
dysfunction in patients who had sustained acute ischemic stroke.</p><p>Stroke is one of the most important causes of death and long-term disability. Control
of the risk factors can prevent the development of stroke<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Recent studies have
shown a relation between EFT and stroke<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Akil et al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> demonstrated for the
first time the association between EFT and cerebral ischemic stroke.</p><p>As mentioned before, EAT has the same blood supply as the adjacent myocardium and
also shown paracrine functions. This causes risk for cardiac structures due to local
pathogenic inflammatory effects<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. A computed tomography (CT) evaluation from the
Framingham Heart study showed that pericardial fat volume could predict atrial
fibrillation (AF) risk independently of other measurements of
adiposity<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Tsao et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup> showed that periatrial EAT was
increased and was correlated with atrial dysfunction in patients with AF-related
stroke.</p><p>EAT, a metabolically active tissue can induce fibrotic changes on the atrial
myocardium by releasing proinflammatory cytokines and adipo-fibrokines. EAT can be
an infiltrated adipocyte on the atrial myocardium. This can cause blockage of local
conduction and promote the micro-reentry circuit. As a result, the occurrence of AF
increases. Two potential mechanisms can be proposed for this association: firstly,
the actions of proinflammatory cytokines and adipo-fibrokines released from EAT,
such as activin A, adiponectin, and resistin, which can induce fibrotic changes on
the atrial myocardium<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r11" ref-type="bibr">11</xref>]</sup>; and secondly, adipocyte infiltration on the atrial
myocardium, which can cause blockage of local conduction and promote the
micro-reentry circuit; and potential modulations of the autonomic nervous system by
the ganglionic plexus within the EAT, which may influence the occurrence of AF. In
this study, we comprehensively assessed the relationship between the
CHA<sub>2</sub>DS<sub>2</sub>-VASc score with EFT around the right ventricle.
They were independently associated with each other, based on a multivariate
analysis. Consequently, we can say that EFT is a risk indicator for stroke.</p><sec><title>Study Limitations</title><p>The relatively limited number of patients could limit the strength of the results
and the conclusion obtained from this study. Echocardiographic EAT is a linear
measurement, and thus it may not assess the total epicardial fat volume that
varies at several myocardial locations. As a result of EAT being a metabolically
active tissue, inflammatory cytokines and inflammatory markers could be
investigated in future studies.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, our findings suggest that echocardiographic EFT measurement could
provide additional information on assessing cardiovascular risks, such as
thromboembolic events, and individuals with increasing EFT should receive more
attention to reduce unfavorable cardiovascular risk factors and the development of
future cardiovascular events.</p><table-wrap id="t7" orientation="portrait" position="float"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SG</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FK</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TO</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; agreement to be
accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EV</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Department of Cardiology, Suleyman Demirel
University, Medical School, Isparta, Turkey.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2015 DALYs and HALE Collaborators</collab></person-group><article-title>Global, regional, and national disability-adjusted life-years
(DALYs) for 315 diseases and injuries and healthy life expectancy (HALE),
1990-2015: a systematic analysis for the Global Burden of Disease Study
2015</article-title><source>Lancet</source><year>2016</year><volume>388</volume><issue>10053</issue><fpage>1603</fpage><lpage>1658</lpage><pub-id pub-id-type="pmid">27733283</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobellis</surname><given-names>G</given-names></name><name><surname>Malavazos</surname><given-names>AE</given-names></name><name><surname>Corsi</surname><given-names>MM</given-names></name></person-group><article-title>Epicardial fat: from the biomolecular aspects to the clinical
practice</article-title><source>Int J Biochem Cell Biol</source><year>2011</year><volume>43</volume><issue>12</issue><fpage>1651</fpage><lpage>1654</lpage><pub-id pub-id-type="pmid">21967993</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seng&#x000fc;l</surname><given-names>C</given-names></name><name><surname>&#x000d6;zveren</surname><given-names>O</given-names></name></person-group><article-title>Epicardial adipose tissue: a review of physiology,
pathophysiology, and clinical applications</article-title><source>Anadolu Kardiyol Derg</source><year>2013</year><volume>13</volume><issue>3</issue><fpage>261</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">23395709</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobellis</surname><given-names>G</given-names></name><name><surname>Willens</surname><given-names>HJ</given-names></name></person-group><article-title>Echocardiographic epicardial fat: a review of research and
clinical applications</article-title><source>J Am Soc Echocardiogr</source><year>2009</year><volume>22</volume><issue>12</issue><fpage>1311</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">19944955</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gul</surname><given-names>I</given-names></name><name><surname>Zungur</surname><given-names>M</given-names></name><name><surname>Aykan</surname><given-names>AC</given-names></name><name><surname>Gokdeniz</surname><given-names>T</given-names></name><name><surname>Kalaycioglu</surname><given-names>E</given-names></name><name><surname>Turan</surname><given-names>T</given-names></name><etal/></person-group><article-title>The relationship between GRACE score and epicardial fat thickness
in non-STEMI patients</article-title><source>Arq Bras Cardiol</source><year>2016</year><volume>106</volume><issue>3</issue><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">26885974</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akil</surname><given-names>E</given-names></name><name><surname>Akil</surname><given-names>MA</given-names></name><name><surname>Varol</surname><given-names>S</given-names></name><name><surname>&#x000d6;zdemir</surname><given-names>HH</given-names></name><name><surname>Y&#x000fc;cel</surname><given-names>Y</given-names></name><name><surname>Arslan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Echocardiographic epicardial fat thickness and neutrophil to
lymphocyte ratio are novel inflammatory predictors of cerebral ischemic
stroke</article-title><source>J Stroke Cerebrovasc Dis</source><year>2014</year><volume>23</volume><issue>9</issue><fpage>2328</fpage><lpage>2334</lpage><pub-id pub-id-type="pmid">25200242</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>January</surname><given-names>CT</given-names></name><name><surname>Wann</surname><given-names>LS</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Cigarroa</surname><given-names>JE</given-names></name><name><surname>Cleveland Jr</surname><given-names>JC</given-names></name><etal/></person-group><article-title>2014 AHA/ACC/HRS guideline for the management of patients with
atrial fibrillation: a report of the American College of Cardiology/American
Heart Association Task Force on practice guidelines and the Heart Rhythm
Society</article-title><source>Circulation</source><year>2014</year><volume>130</volume><issue>23</issue><fpage>e199</fpage><lpage>e267</lpage><pub-id pub-id-type="pmid">24682347</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahn</surname><given-names>DJ</given-names></name><name><surname>DeMaria</surname><given-names>A</given-names></name><name><surname>Kisslo</surname><given-names>J</given-names></name><name><surname>Weyman</surname><given-names>A</given-names></name></person-group><article-title>Recommendations regarding quantitation in M-mode
echocardiography: results of a survey of echocardiographic
measurements</article-title><source>Circulation</source><year>1978</year><volume>58</volume><issue>6</issue><fpage>1072</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">709763</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazurek</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zalewski</surname><given-names>A</given-names></name><name><surname>Mannion</surname><given-names>JD</given-names></name><name><surname>Diehl</surname><given-names>JT</given-names></name><name><surname>Arafat</surname><given-names>H</given-names></name><etal/></person-group><article-title>Human epicardial adipose tissue is a source of inflammatory
mediators</article-title><source>Circulation</source><year>2003</year><volume>108</volume><issue>20</issue><fpage>2460</fpage><lpage>2466</lpage><pub-id pub-id-type="pmid">14581396</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akdag</surname><given-names>S</given-names></name><name><surname>Simsek</surname><given-names>H</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name><name><surname>Akyol</surname><given-names>A</given-names></name><name><surname>Duz</surname><given-names>R</given-names></name><name><surname>Babat</surname><given-names>N</given-names></name></person-group><article-title>Association of epicardial adipose tissue thickness and
inflammation parameters with CHA2DS2-VASASc score in patients with
nonvalvular atrial fibrillation</article-title><source>Ther Clin Risk Manag</source><year>2015</year><volume>11</volume><fpage>1675</fpage><lpage>1681</lpage><pub-id pub-id-type="pmid">26609234</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobellis</surname><given-names>G</given-names></name><name><surname>Corradi</surname><given-names>D</given-names></name><name><surname>Sharma</surname><given-names>AM</given-names></name></person-group><article-title>Epicardial adipose tissue: anatomic, biomolecular and clinical
relationships with the heart</article-title><source>Nature Clin Pract Cardiovasc Med</source><year>2005</year><volume>2</volume><issue>10</issue><fpage>536</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">16186852</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobellis</surname><given-names>G</given-names></name><name><surname>Bianco</surname><given-names>AC</given-names></name></person-group><article-title>Epicardial adipose tissue: emerging physiological,
pathophysiological and clinical features</article-title><source>Trends Endocrinol Metab</source><year>2011</year><volume>22</volume><issue>11</issue><fpage>450</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">21852149</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avanzas</surname><given-names>P</given-names></name><name><surname>Arroyo-Espliguero</surname><given-names>R</given-names></name><name><surname>Cos&#x000ed;n-Sales</surname><given-names>J</given-names></name><name><surname>Aldama</surname><given-names>G</given-names></name><name><surname>Pizzi</surname><given-names>C</given-names></name><name><surname>Quiles</surname><given-names>J</given-names></name><etal/></person-group><article-title>Markers of inflammation and multiple complex stenoses
(pancoronary plaque vulnerability) in patients with non-ST segment elevation
acute coronary syndromes</article-title><source>Heart</source><year>2004</year><volume>90</volume><issue>8</issue><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">15253949</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anrather</surname><given-names>J</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name></person-group><article-title>Inflammation and stroke: an overview</article-title><source>Neurotherapeutics</source><year>2016</year><volume>13</volume><issue>4</issue><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">27730544</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname><given-names>AM</given-names></name><name><surname>Prokop</surname><given-names>M</given-names></name><name><surname>Roos</surname><given-names>CJ</given-names></name><name><surname>Meijs</surname><given-names>MF</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name><name><surname>Rutten</surname><given-names>A</given-names></name><etal/></person-group><article-title>Peri-coronary epicardial adipose tissue is related to
cardiovascular risk factors and coronary artery calcification in
post-menopausal women</article-title><source>Eur Heart J</source><year>2007</year><volume>29</volume><issue>6</issue><fpage>777</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">18156138</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobellis</surname><given-names>G</given-names></name><name><surname>Assael</surname><given-names>F</given-names></name><name><surname>Ribaudo</surname><given-names>MC</given-names></name><name><surname>Zappaterreno</surname><given-names>A</given-names></name><name><surname>Alessi</surname><given-names>G</given-names></name><name><surname>Di Mario</surname><given-names>U</given-names></name><etal/></person-group><article-title>Epicardial fat from echocardiography: a new method for visceral
adipose tissue prediction</article-title><source>Obes Res</source><year>2003</year><volume>11</volume><issue>2</issue><fpage>304</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">12582228</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobellis</surname><given-names>G</given-names></name><name><surname>Ribaudo</surname><given-names>MC</given-names></name><name><surname>Assael</surname><given-names>F</given-names></name><name><surname>Vecci</surname><given-names>E</given-names></name><name><surname>Tiberti</surname><given-names>C</given-names></name><name><surname>Zappaterreno</surname><given-names>A</given-names></name><etal/></person-group><article-title>Echocardiographic epicardial adipose tissue is related to
anthropometric and clinical parameters of metabolic syndrome: a new
indicator of cardiovascular risk</article-title><source>J Clin Endocrinol Metab</source><year>2003</year><volume>88</volume><issue>11</issue><fpage>5163</fpage><lpage>5168</lpage><pub-id pub-id-type="pmid">14602744</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobellis</surname><given-names>G</given-names></name><name><surname>Ribaudo</surname><given-names>MC</given-names></name><name><surname>Zappaterreno</surname><given-names>A</given-names></name><name><surname>Iannucci</surname><given-names>CV</given-names></name><name><surname>Leonetti</surname><given-names>F</given-names></name></person-group><article-title>Relation between epicardial adipose tissue and left ventricular
mass</article-title><source>Am J Cardiol</source><year>2004</year><volume>94</volume><issue>8</issue><fpage>1084</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">15476634</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cetin</surname><given-names>M</given-names></name><name><surname>Cakici</surname><given-names>M</given-names></name><name><surname>Polat</surname><given-names>M</given-names></name><name><surname>Suner</surname><given-names>A</given-names></name><name><surname>Zencir</surname><given-names>C</given-names></name><name><surname>Ardic</surname><given-names>I</given-names></name></person-group><article-title>Relation of epicardial fat thickness with carotid intima-media
thickness in patients with type 2 diabetes mellitus</article-title><source>Int J Endocrinol</source><year>2013</year><volume>2013</volume><elocation-id>769175</elocation-id><pub-id pub-id-type="pmid">23762053</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname><given-names>M</given-names></name><name><surname>Turak</surname><given-names>O</given-names></name><name><surname>Akyel</surname><given-names>A</given-names></name><name><surname>Grbovi&#x000e7;</surname><given-names>E</given-names></name><name><surname>Mendi</surname><given-names>MA</given-names></name><name><surname>&#x000d6;ks&#x000fc;z</surname><given-names>F</given-names></name><etal/></person-group><article-title>Increased epicardial adipose tissue thickness is linked to aortic
stiffness in patients with primary hypertension</article-title><source>Blood Press</source><year>2014</year><volume>23</volume><issue>4</issue><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">24328851</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altun</surname><given-names>I</given-names></name><name><surname>Unal</surname><given-names>Y</given-names></name><name><surname>Basaran</surname><given-names>O</given-names></name><name><surname>Akin</surname><given-names>F</given-names></name><name><surname>Emir</surname><given-names>GK</given-names></name><name><surname>Kutlu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Increased epicardial fat thickness correlates with aortic
stiffness and N-terminal pro-brain natriuretic peptide levels in acute
ischemic stroke patients</article-title><source>Texas Heart Inst J</source><year>2016</year><volume>43</volume><issue>3</issue><fpage>220</fpage><lpage>226</lpage></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>HM</given-names></name><name><surname>Hu</surname><given-names>WC</given-names></name><name><surname>Tsai</surname><given-names>PH</given-names></name><name><surname>Lee</surname><given-names>CL</given-names></name><name><surname>Liu</surname><given-names>FC</given-names></name><name><surname>Wang</surname><given-names>HH</given-names></name><etal/></person-group><article-title>The abundance of epicardial adipose tissue surrounding left
atrium is associated with the occurrence of stroke in patients with atrial
fibrillation</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><issue>14</issue><elocation-id>e3260</elocation-id><pub-id pub-id-type="pmid">27057876</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanassoulis</surname><given-names>G</given-names></name><name><surname>Massaro</surname><given-names>JM</given-names></name><name><surname>O'Donnell</surname><given-names>CJ</given-names></name><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Pericardial fat is associated with prevalent atrial fibrillation:
the Framingham Heart Study</article-title><source>Cir Arrhythm Electrophysiol</source><year>2010</year><volume>3</volume><issue>4</issue><fpage>345</fpage><lpage>350</lpage></element-citation></ref></ref-list></back></article>